Hormone-Dependent Cancers: Molecular Mechanisms and Therapeutical Implications.

Cells

Department of Gynecolgy and Obstetrics, University Medicine Göttingen, Robert Koch Str. 40, 37075 Göttingen, Germany.

Published: December 2022

Hormone-dependent cancers of the breast and prostate are the most common cancers in women and men, respectively [...].

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818209PMC
http://dx.doi.org/10.3390/cells12010110DOI Listing

Publication Analysis

Top Keywords

hormone-dependent cancers
8
cancers molecular
4
molecular mechanisms
4
mechanisms therapeutical
4
therapeutical implications
4
implications hormone-dependent
4
cancers breast
4
breast prostate
4
prostate common
4
common cancers
4

Similar Publications

Aromatase plays a crucial role in the conversion of androgens to oestrogens and is often overexpressed in hormone-dependent tumours, particularly breast cancer. [18F]BIBD-071, which has excellent binding affinity for aromatase and good pharmacokinetics, has potential for the diagnosis and treatment of aromatase-related diseases. The MCF-7 cell line, which is hormone receptor-positive (HR+), was used in the assessment of the novel [18F]-labelled radiotracer [18F]BIBD-071 via positron emission tomography (PET) imaging of an HR+ breast cancer xenograft model.

View Article and Find Full Text PDF

Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial therapeutic development, providing fast and reversible suppression of gonadotropins by directly blocking GnRH-R. Unlike typical GnRH agonists, these antagonists prevent the early hormonal flare, have a faster onset of action, and have a lower risk of cardiovascular problems.

View Article and Find Full Text PDF

Background: Current treatment strategies for hormone-dependent breast cancers, including adjuvant endocrine therapy, often fail due to persistence of breast cancer stem cells (brCSCs), which are significant contributors to tumor recurrence and treatment resistance. Therefore, gaining deeper insights into the molecular regulators driving breast cancer aggressiveness is important. Moreover, given the complexities and expenses involved in developing new pharmacological agents, the strategic repurposing of existing FDA-approved drugs to target these key molecular pathways presents a compelling approach for identifying novel therapeutic interventions aimed at mitigating tumor refractoriness.

View Article and Find Full Text PDF

Breast cancer is one of the most common cancers found in women worldwide. Besides the availability of clinical drugs, drug resistance and considerable side effects are concerning issues driven the needs for the discovery of novel anticancer agents. Aromatase inhibition is one of the effective strategies for management of hormone-dependent breast cancer.

View Article and Find Full Text PDF

Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities.

Life Sci

February 2025

Department of Gynecology and Obstetrics, Division of Reproductive Sciences & Women's Health Research, Johns Hopkins Medicine, Baltimore, MD 21205, USA. Electronic address:

Progesterone (P4) is a vital female sex hormone involved in various physiological processes, including the maintenance of the endometrium, mammary gland development, and bone health. Beyond its reproductive roles, P4 is implicated in the pathogenesis of hormone-dependent conditions like uterine fibroids, the most common benign tumors in women, which can severely affect quality of life and fertility. Traditionally, estrogen was considered the primary driver of fibroid growth, but recent research highlights the significant role of P4 in fibroid growth.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!